Literature DB >> 24907710

Utility of recombinant proteins LID-1 and PADL in screening for Mycobacterium leprae infection and leprosy.

Marilena Maria de Souza1, Eduardo M Netto2, Maria Nakatani3, Malcolm S Duthie4.   

Abstract

BACKGROUND: Despite the widespread use of multidrug therapy, leprosy remains an important public health concern in many regions. Detection is generally limited to clinical exam.
METHODS: As a two-tiered active case finding strategy, we used the LID-1 (leprosy IDRI diagnostic-1), and PADL (protein advances for the diagnosis of leprosy) antigens for serological examination of 2526 individuals randomly selected from 10 472 residents in a leprosy hyperendemic area (Cajazeiras, Paraiba, Brazil). Almost all seropositive (95%) and a subset of seronegative (17%) subjects then underwent clinical evaluations.
RESULTS: Prevalence of clinically apparent leprosy was 2.3% (19 cases among 834 fully examined individuals). LID-1 and PADL demonstrated a high sensitivity for supporting leprosy diagnosis at 89% and 87%, with positive predictive values (PPV) of 3.5% and 3.7%. The specificity for clinically apparent leprosy was low at 42% and 38%, respectively, and was likely reduced due to the presence of many asymptomatic individuals infected with Mycobacterium leprae.
CONCLUSIONS: Our data indicate the utility of the LID-1 and PADL antigens as primary screening tools for the detection of M. leprae infection and identification of leprosy patients. The follow-up of seropositive subjects could clarify the predictive value and utility of detecting anti-LID-1 and PADL antibodies within leprosy control programs.
© The Author 2014. Published by Oxford University Press on behalf of Royal Society of Tropical Medicine and Hygiene. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Brazil; Diagnosis; Leprosy; Mycobacterium leprae; Serology

Mesh:

Substances:

Year:  2014        PMID: 24907710     DOI: 10.1093/trstmh/tru093

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  8 in total

1.  Insight into the evolution and origin of leprosy bacilli from the genome sequence of Mycobacterium lepromatosis.

Authors:  Pushpendra Singh; Andrej Benjak; Verena J Schuenemann; Alexander Herbig; Charlotte Avanzi; Philippe Busso; Kay Nieselt; Johannes Krause; Lucio Vera-Cabrera; Stewart T Cole
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-23       Impact factor: 11.205

2.  Development of LepReact, a defined skin test for paucibacillary leprosy and low-level M. leprae infection.

Authors:  Malcolm S Duthie; Maria T Pena; Amit P Khandhar; Alessandro Picone; Zachary MacMIllen; Richard W Truman; Linda B Adams; Steven G Reed
Journal:  Appl Microbiol Biotechnol       Date:  2020-03-10       Impact factor: 4.813

3.  Antigen-specific assessment of the immunological status of various groups in a leprosy endemic region.

Authors:  Angélica da Conceição Oliveira Coelho Fabri; Ana Paula Mendes Carvalho; Sergio Araujo; Luiz Ricardo Goulart; Ana Márcia Menezes de Mattos; Henrique Couto Teixeira; Isabela Maria Bernardes Goulart; Malcolm S Duthie; Rodrigo Correa-Oliveira; Francisco Carlos Félix Lana
Journal:  BMC Infect Dis       Date:  2015-05-30       Impact factor: 3.090

4.  A novel integrated molecular and serological analysis method to predict new cases of leprosy amongst household contacts.

Authors:  Rafael Silva Gama; Márcio Luís Moreira de Souza; Euzenir Nunes Sarno; Milton Ozório de Moraes; Aline Gonçalves; Mariane M A Stefani; Raúl Marcel González Garcia; Lucia Alves de Oliveira Fraga
Journal:  PLoS Negl Trop Dis       Date:  2019-06-10

5.  Prospects for new leprosy diagnostic tools, a narrative review considering ELISA and PCR assays.

Authors:  Rafael Silva Gama; Lázaro Azevedo Leite; Lívia Tavares Colombo; Lúcia Alves de Oliveira Fraga
Journal:  Rev Soc Bras Med Trop       Date:  2020-11-25       Impact factor: 1.581

6.  Multibacillary leprosy patients with high and persistent serum antibodies to leprosy IDRI diagnostic-1/LID-1: higher susceptibility to develop type 2 reactions.

Authors:  Danielle de Freitas Mizoguti; Emerith Mayra Hungria; Aline Araújo Freitas; Regiane Morillas Oliveira; Ludimila Paula Vaz Cardoso; Mauricio Barcelos Costa; Ana Lúcia Maroclo Sousa; Malcolm S Duthie; Mariane Martins Araújo Stefani
Journal:  Mem Inst Oswaldo Cruz       Date:  2015-11       Impact factor: 2.743

Review 7.  Anti-PGL-1 Positivity as a Risk Marker for the Development of Leprosy among Contacts of Leprosy Cases: Systematic Review and Meta-analysis.

Authors:  Maria Lucia F Penna; Gerson O Penna; Paula C Iglesias; Sonia Natal; Laura C Rodrigues
Journal:  PLoS Negl Trop Dis       Date:  2016-05-18

8.  Evaluation of antibody detection against the NDO-BSA, LID-1 and NDO-LID antigens as confirmatory tests to support the diagnosis of leprosy in Yunnan province, southwest China.

Authors:  Liu Jian; Shang Xiujian; You Yuangang; Xing Yan; Yuan Lianchao; Malcolm S Duthie; Wen Yan
Journal:  Trans R Soc Trop Med Hyg       Date:  2020-02-07       Impact factor: 2.184

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.